Detalles de la búsqueda
1.
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.
Mol Ther
; 23(2): 396-406, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25363716
2.
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Cancer Immunol Immunother
; 59(6): 921-31, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20101507
3.
The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
PLoS One
; 9(5): e97495, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24866126
4.
The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.
Oncoimmunology
; 3(9): e955697, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25941622
5.
Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.
Hum Gene Ther Methods
; 23(3): 213-24, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22871260
6.
T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Hum Gene Ther
; 23(2): 187-201, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21958294
7.
TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Mol Immunol
; 47(7-8): 1411-20, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20303179
Resultados
1 -
7
de 7
1
Próxima >
>>